Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 5:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 3,320 matching trials from the live ClinicalTrials.gov search.
Conditions
Head and Neck Cancer, HPV
Interventions
Volrustomig, Carboplatin, Paclitaxel
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Cervical Intraepithelial Neoplasia, Cervical Neoplasms, Oropharyngeal Neoplasms, Squamous Intraepithelial Lesions of the Cervix, Hematologic Malignacies
Interventions
GeneTherapy
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2050
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Dysphagia
Interventions
Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES)
Device
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
14
States / cities
Scottsdale, Arizona • San Diego, California • Evanston, Illinois + 8 more
Conditions
Head And Neck Cancer
Interventions
Erlotinib, RAD001
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cancer
Interventions
Oral lapatinib tablets or placebo tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
20
States / cities
Denver, Colorado • Indianapolis, Indiana • Overland Park, Kansas + 17 more
Conditions
Squamous Cell Carcinoma of Mouth
Interventions
laboratory biomarker analysis, preventative dietary intervention
Other
Lead sponsor
Amit Agrawal
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Breast Neoplasms, Urinary Bladder Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Colorectal Neoplasms, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
SGN-2FF, pembrolizumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • Duarte, California • Aurora, Colorado + 8 more
Conditions
Oropharynx Cancer
Interventions
Radiation therapy (5 days for 7 weeks), Radiation therapy (5 days for 6 weeks), Cisplatin
Radiation · Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Head and Neck Neoplasm
Interventions
Laryngoscopy, Tracheal Intubation
Device · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Interventions
bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Head and Neck Cancer, Xerostomia
Interventions
Pilocarpine, ALTENS
Drug · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
16
States / cities
San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 11 more
Conditions
Cancer, Breast Cancer, Brain Cancer, Central Nervous System Cancer, Colorectal Cancer, Esophageal Cancer, Gynecologic Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Melanoma, Blood Cancer, Lung Cancer, Acceptance and Commitment Therapy, Mind-Body Therapies, Psychosocial Intervention
Interventions
Mind Over Matter (MOM)
Other
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Fairfax, Virginia
Completed Phase 2 Interventional Results available

Trial of LBH589 in Metastatic Thyroid Cancer

NCT01013597
Conditions
Thyroid Carcinoma
Interventions
LBH589
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Green Bay, Wisconsin • Madison, Wisconsin • Milwaukee, Wisconsin
Recruiting No phase listed Observational Accepts healthy volunteers

Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions

NCT03160274
Conditions
Pheochromocytoma, Paraganglioma, Inherited Cancer Syndrome, Associated Conditions, Kidney Neoplasms, Bone Cancer, Thyroid Neoplasms, Other Cancer
Interventions
Genetic screening
Genetic
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2030
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Head and Neck Cancer
Interventions
behavior
Behavioral
Lead sponsor
Edward Hines Jr. VA Hospital
Federal
Eligibility
30 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
Hines, Illinois
Completed No phase listed Observational Accepts healthy volunteers

Salivary Proteins in Disease and Health

NCT00100204
Conditions
Diabetes Mellitus, Sarcoidosis, Dental Caries, Sjorgren's Syndrome, Cystinosis, Head and Neck Neoplasms
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Head and Neck Cancer
Interventions
filgrastim, doxorubicin hydrochloride, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
Biological · Drug · Procedure + 1 more
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
16 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
2
States / cities
Belleville, New Jersey • Paterson, New Jersey
Conditions
Head and Neck Cancer
Interventions
Erlotinib (Tarceva), Intra-arterial Cisplatin (PLAT), Radiation Therapy (RAD)
Drug · Radiation
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Springfield, Illinois
Conditions
Cancer
Interventions
management of therapy complications, massage therapy, pain therapy, psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting Not applicable Interventional Accepts healthy volunteers

De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers

NCT06554158
Conditions
Oropharynx Cancer
Interventions
Radiation Therapy
Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Head and Neck Cancer, Oral Complications of Radiation Therapy, Radiation Toxicity
Interventions
cisplatin, fluorouracil, Intensity modulated radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
17
States / cities
Birmingham, Alabama • Davis, California • Sacramento, California + 13 more
Conditions
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
Interventions
Pembrolizumab (KEYTRUDA®) and PDS0101
Combination Product
Lead sponsor
PDS Biotechnology Corp.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
18
States / cities
Greenbrae, California • San Francisco, California • Jacksonville, Florida + 15 more
Conditions
Parathyroid Adenoma, Parathyroid Neoplasms, Parathyroid Hyperplasia, Parathyroid Cancer, Hypercalcemia, Primary Hyperparathyroidism
Interventions
NIRAF Detection Technology
Device
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
G17DT Immunogen, cisplatin, fluorouracil
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Los Angeles, California